ISDA

Entry Detail

PDB ID:

3R4O

Keywords:

Title:

Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2011-03-17

Release Date:

2011-04-27

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.65 Å

R-Value Free:

0.28

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Heat shock protein HSP 90-alpha
Chain IDs:A, B
Chain Length:226
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P07900 Pfam ID:PF13589 EC:3.6.4.10

Ligand Molecules

FU3

Primary Citation

Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.

Zehnder, L, Bennett, M, Meng, J, Huang, B, Ninkovic, S, Wang, F, Braganza, J, Tatlock, J, Jewell, T, Zhou, J.Z, Burke, B, Wang, J, Maegley, K, Mehta, P.P, Yin, M.J, Gajiwala, K.S, Hickey, M.J, Yamazaki, S, Smith, E, Kang, P, Sistla, A, Dovalsantos, E, Gehring, M.R, Kania, R, Wythes, M, Kung, P.P.Show

J.Med.Chem. 54 3368 3385 (2011)

PMID: 21438541 DOI: 10.1021/jm200128m

Abstact

A novel class of heat shock protein 90 (Hsp90) inhibitors was discovered by high-throughput screening and was subsequently optimized using a combination of structure-based design, parallel synthesis, and the application of medicinal chemistry principles. Through this process, the biochemical and cell-based potency of the original HTS lead were substantially improved along with the corresponding metabolic stability properties. These efforts culminated with the identification of a development candidate (compound 42) which displayed desired PK/PD relationships, significant efficacy in a melanoma A2058 xenograft tumor model, and attractive DMPK profiles.

Legend

Protein

Chemical

Disease

Primary Citation of related structures